CY1112014T1 - Συνθεσεις αντιβακτηριακων εμβολιων - Google Patents

Συνθεσεις αντιβακτηριακων εμβολιων

Info

Publication number
CY1112014T1
CY1112014T1 CY20111100401T CY111100401T CY1112014T1 CY 1112014 T1 CY1112014 T1 CY 1112014T1 CY 20111100401 T CY20111100401 T CY 20111100401T CY 111100401 T CY111100401 T CY 111100401T CY 1112014 T1 CY1112014 T1 CY 1112014T1
Authority
CY
Cyprus
Prior art keywords
vaccine compositions
antibacterial vaccine
gram
negative bacterial
virulence genes
Prior art date
Application number
CY20111100401T
Other languages
Greek (el)
English (en)
Inventor
David E Lowery
Troy E Fuller
Michael J Kennedy
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of CY1112014T1 publication Critical patent/CY1112014T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CY20111100401T 2001-03-15 2011-04-18 Συνθεσεις αντιβακτηριακων εμβολιων CY1112014T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions
EP02705915A EP1368456B1 (en) 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions

Publications (1)

Publication Number Publication Date
CY1112014T1 true CY1112014T1 (el) 2015-11-04

Family

ID=25201919

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100401T CY1112014T1 (el) 2001-03-15 2011-04-18 Συνθεσεις αντιβακτηριακων εμβολιων

Country Status (18)

Country Link
US (2) US6790950B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368456B1 (cg-RX-API-DMAC7.html)
JP (2) JP2005502315A (cg-RX-API-DMAC7.html)
AR (2) AR035745A1 (cg-RX-API-DMAC7.html)
AT (1) ATE500316T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002240033B2 (cg-RX-API-DMAC7.html)
CA (2) CA2438315C (cg-RX-API-DMAC7.html)
CY (1) CY1112014T1 (cg-RX-API-DMAC7.html)
DE (1) DE60239318D1 (cg-RX-API-DMAC7.html)
DK (1) DK1368456T3 (cg-RX-API-DMAC7.html)
ES (1) ES2362041T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008296A (cg-RX-API-DMAC7.html)
NZ (1) NZ528208A (cg-RX-API-DMAC7.html)
PE (1) PE20021008A1 (cg-RX-API-DMAC7.html)
PT (1) PT1368456E (cg-RX-API-DMAC7.html)
SI (1) SI1368456T1 (cg-RX-API-DMAC7.html)
TW (4) TWI334884B (cg-RX-API-DMAC7.html)
WO (1) WO2002075507A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP2010505831A (ja) * 2006-10-05 2010-02-25 ニューヨーク ブラッド センター， インコーポレイテッド 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
WO2010002989A2 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
WO2015066292A1 (en) * 2013-11-01 2015-05-07 Merial Limited Attenuated pasteurella multocidavaccines & methods of making & use thereof
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
HU219535B (hu) 1991-03-05 2001-05-28 Wellcome Foundation Ltd. Rekombináns proteineket expresszáló, attenuált baktériumokat tartalmazó vakcinák
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
AU5591694A (en) 1992-11-06 1994-06-08 Regents Of The University Of Minnesota Composition protective against (p. multocida) pasteurellosis infection
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
AU1662595A (en) 1994-01-28 1995-08-15 Herbert Altmann Method of determining the activity of a regulatory factor, and use of the method
RU2370541C2 (ru) 1994-12-09 2009-10-20 Имерджент Продакт Дивелопмент Юк Лимитед Vgc2 днк salmonella typhimurium, мутантная бактерия, обладающая пониженной способностью к адаптации к условиям окружающей среды, и способ ее получения
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
EP0939830B1 (en) * 1996-09-06 2008-12-31 Peter Ruhdal Jensen A method of improving the production of a desired product from a cell
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
US6376211B1 (en) * 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase
AU2001258373A1 (en) * 2000-04-27 2001-11-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
JP2011097938A (ja) 2011-05-19
EP1368456B1 (en) 2011-03-02
US7476391B2 (en) 2009-01-13
WO2002075507B1 (en) 2003-12-11
AR035745A1 (es) 2004-07-07
SI1368456T1 (sl) 2011-06-30
DK1368456T3 (da) 2011-05-23
JP2005502315A (ja) 2005-01-27
AR071888A2 (es) 2010-07-21
TW201040261A (en) 2010-11-16
WO2002075507A2 (en) 2002-09-26
PT1368456E (pt) 2011-06-01
MXPA03008296A (es) 2007-05-28
DE60239318D1 (de) 2011-04-14
TWI335935B (en) 2011-01-11
CA2438315C (en) 2014-09-02
PE20021008A1 (es) 2002-11-13
TWI335934B (en) 2011-01-11
ATE500316T1 (de) 2011-03-15
CA2438315A1 (en) 2002-09-26
NZ528208A (en) 2008-04-30
TW201040262A (en) 2010-11-16
TWI334884B (en) 2010-12-21
CA2852293A1 (en) 2002-09-26
ES2362041T3 (es) 2011-06-27
US6790950B2 (en) 2004-09-14
WO2002075507A3 (en) 2003-09-12
TWI328035B (en) 2010-08-01
US20040110268A1 (en) 2004-06-10
AU2002240033B2 (en) 2007-11-08
US20050003512A1 (en) 2005-01-06
EP1368456A2 (en) 2003-12-10
TW200916577A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
CY1112014T1 (el) Συνθεσεις αντιβακτηριακων εμβολιων
ATE485056T1 (de) Verbesserte impfstoffe
CY1106431T1 (el) Γονοκοκκικες πρωτεϊνες και νουκλεϊκα οξεα
CY1105194T1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
DK1103564T3 (da) Cancerantigener baseret på tumorsuppressorgen WT1-produkt
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
WO2000061724A3 (en) Anti-bacterial vaccine compositions
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
ATE355104T1 (de) Haarbehandlungsmittel
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
CY1108300T1 (el) Παρασκευασματα ευγενων μεταλλων και παρασκευασματα λουστρων για την αμεση και εμμεση μεταξοτυπια
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
WO1999001473A3 (en) Anti-bacterial methods and materials
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
NO20013102D0 (no) Gener, proteiner og deres anvendelse
BRPI0413509A (pt) uso de antibióticos de quinolona
PL372769A1 (en) Cyanoguanidine prodrugs
CY1106211T1 (el) Φαρμακευτικα παρασκευασματα πepιεχοντας εκχυλισματα της ισοφλαβονης της σογιας και προβιοτικους μικροοργανισμους
DK1615656T3 (da) Immunmodulerende produkt opnået ud fra en Bifidobacterium-kultur og præparater indeholdende samme
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form